The world's first personalized mRNA cancer vaccine halves the risk of patients dying or the disease recurring, with a 49% lower risk noted after three years of receiving the vaccine.
The vaccine in combination with Keytruda showed a 74.8% recurrence-free survival rate, compared to 55.6% for Keytruda alone, showcasing the effectiveness of this innovative treatment approach.
[
Collection
]
[
|
...
]